Functional Dyspepsia

4
Pipeline Programs
4
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
1
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
2 programs
1
1
Itopride Hydrochloride 150 mg extended release tabletsPhase 31 trial
ItopridePhase 2/31 trial
Active Trials
NCT00272103Completed500Est. Jan 2002
NCT06217393Active Not Recruiting564Est. Feb 2025
E
EisaiChina - Liaoning
1 program
1
RabeprazolePhase 2Small Molecule1 trial
Active Trials
NCT01089543Completed338Est. Aug 2011
Astellas
AstellasChina - Shenyang
1 program
1
YM443Phase 13 trials
Active Trials
NCT00850746Completed80Est. Apr 2009
NCT00764374Completed412Est. Dec 2009
NCT00102310Completed416Est. Mar 2006
Hamilton medical
Hamilton medicalSwitzerland - Bonaduz
1 program
Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients PresentingN/A1 trial
Active Trials
NCT03868267UnknownEst. Dec 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbottItopride Hydrochloride 150 mg extended release tablets
AstellasYM443
AbbottItopride
EisaiRabeprazole
AstellasYM443
AstellasYM443
Hamilton medicalJapanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting

Clinical Trials (7)

Total enrollment: 2,310 patients across 7 trials

NCT06217393AbbottItopride Hydrochloride 150 mg extended release tablets

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Start: Feb 2024Est. completion: Feb 2025564 patients
Phase 3Active Not Recruiting
NCT00764374AstellasYM443

A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia

Start: Aug 2008Est. completion: Dec 2009412 patients
Phase 3Completed
NCT00272103AbbottItopride

Itopride in Functional Dyspepsia:a Dose Finding Study

Start: Dec 2000Est. completion: Jan 2002500 patients
Phase 2/3Completed
NCT01089543EisaiRabeprazole

A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)

Start: Apr 2010Est. completion: Aug 2011338 patients
Phase 2Completed
NCT00102310AstellasYM443

YM443 in Subjects With Functional Dyspepsia

Start: Mar 2004Est. completion: Mar 2006416 patients
Phase 2Completed
NCT00850746AstellasYM443

A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults

Start: Feb 2009Est. completion: Apr 200980 patients
Phase 1Completed
NCT03868267Hamilton medicalJapanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting

Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting

Start: May 2019Est. completion: Dec 2023
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space